This inventor holds 10 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Introgen Therapeutics Inc., Crucell Holland B.v.. Active years: 2001-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2011
Title: Zheng Wu: Innovator in Adenovirus Formulations
Introduction
Zheng Wu is a notable inventor based in Sugar Land, Texas, known for his contributions to the field of adenoviral vector formulations. With an impressive portfolio of 10 patents, he has dedicated his work to enhancing the stability and infectivity of viral formulations, thereby advancing the potential for therapeutic applications.
Latest Patents
Among his latest innovations, Zheng Wu developed two key patents focused on liquid adenovirus formulations. These inventions address the critical need for improved long-term storage stability of vector formulations. His research demonstrates that the inclusion of bulking agents, cryoprotectants, and lyoprotectants significantly enhances the properties of adenovirus formulations. As a result, both lyophilized and liquid adenovirus formulations can be stored at 4°C for up to 6 months, maintaining an infectivity range of 60-100% relative to the starting infectivity.
Career Highlights
Zheng Wu's professional journey includes pivotal roles at esteemed companies such as Introgen Therapeutics Inc. and Crucell Holland B.V. His work in these organizations has been instrumental in pushing the boundaries of viral vector technology, contributing to advances in the biotechnology industry.
Collaborations
Throughout his career, Zheng Wu has collaborated with talented professionals like Shuyuan Zhang and Capucine Thwin. These partnerships have fostered innovation and excellence in their shared field of research, underscoring the importance of teamwork in achieving breakthroughs in medical technology.
Conclusion
Zheng Wu's contributions to the field of adenoviral vector formulations exemplify the impact of innovative thinking in biotechnology. His patents not only address essential challenges within the industry but also pave the way for future developments. As he continues to push the bounds of science, Zheng Wu remains a key figure in the advancement of therapeutic applications that utilize adenoviruses.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
